Keros (KROS) news
Recent news
Keros Therapeutics, Inc.: Wells Fargo cuts target price to $18 from $20
AInvest Wire · Aug 4, 2026Keros Therapeutics Inc: Leerink Partners cuts target price to $23 from $30
Keros Therapeutics Inc. (NASDAQ: KROS) has seen a recent adjustment in its price target from Leerink Partners, which reduced its forecast to $23 from a previous $30. This move reflects a broader trend in analyst sentiment, as the stock currently carries a consensus rating of "Hold" based on the…
AInvest Wire · Aug 4, 2026Keros Therapeutics - cash and cash equivalents $257.60 mln as of June 30, 2026
Keros Therapeutics, Inc. (Nasdaq: KROS) reported a significant decline in cash and cash equivalents as of June 30, 2026, standing at $257.60 million, compared to $281.5 million as of March 31, 2026 . This reduction reflects ongoing operational expenditures and research and development activities.…
AInvest Wire · Aug 3, 2026Keros Therapeutics - received $200 mln upfront from Takeda, eligible for over $1.10 bln in milestones
AInvest Wire · Jul 30, 2026Keros Therapeutics - to receive $20 mln development milestone payment from Takeda
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.